Medical devices, healthcare technology and the business of care
PMA approval · P240037

VENTANA MET (SP44) RxDx Assay

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date May 14, 2025

FDA DECISIONP240037

What did the FDA approve?

FDA records P240037 as an original PMA application. The recorded decision is approval, dated May 14, 2025.

FDA approval order statement

Approval for the VENTANA MET (SP44) RxDx Assay. The device is a qualitative immunohistochemical assay using rabbit monoclonal anti-MET, clone SP44, intended for use in the assessment of MET protein in formalin-fixed, paraffin embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) specimens by light microscopy. This assay is for use with OptiView DAB IHC Detection Kit for staining on a BenchMark ULTRA or BenchMark ULTRA PLUS instrument.MET protein expression clinical cut-off is >= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining (3+) in non-squamous NSCLC. VENTANA MET (SP44) RxDx Assay is indicated as an aid in identifying non-squamous NSCLC patients who may be eligible for treatment with EMRELIS (telisotuzumab vedotin-tllv). The results of VENTANA MET (SP44) RxDx Assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls.This product is intended for in vitro diagnostic (IVD) use.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
May 14, 2025

FDA source record

Regulatory record facts

Identifier
P240037
Regulatory pathway
Premarket approval application
Product code
SER
Decision code
APPR
Decision date
May 14, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody, MET.

Product code
SER
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240037 received

    Application receipt date recorded by FDA.

  2. P240037 · FDA decision

    APPR

  3. P240037/S003 · Related supplement

    VENTANA MET (SP44) RxDx Assay

Timeline entries are records held by MedtechLedger for P240037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240037

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records